Arindam Chakraborty, Dipak Kumar Singha, Manas Chakraborty, Payel Mukherjee
Arindam Chakraborty1*, Dipak Kumar Singha1, Manas Chakraborty1, Payel Mukherjee2
1Department of Pharmaceutical Biotechnology, Calcutta Institute of Pharmaceutical Technology and AHS, Uluberia, Howrah, West Bengal, India, 711316.
2Department of Pharmaceutics, M.R. College of Pharmaceutical Sciences and Research, Bira, North 24 Parganas, West Bengal, India, 743702.
Volume - 11,
Issue - 3,
Year - 2021
Therapeutic protein are one of the prime option of biologicals as per their clinical uses. In recent times, uses of therapeutic protein increases day by day. Protein therapeutics are used extensively to treat various diseases like cancer, AIDS etc. Due to recent advancement in pharmaceutical biotechnology the interest towards therapeutic proteins are augmenting nowadays. Various clinical research are going on in this field to treat different diseases and pharmaceutical industries are also make interest on therapeutic proteins. Among the various treatment options therapeutic protein will provide highest chance of clinical success. Some recent clinical trials demonstrate that therapeutic protein may provide the safe and potential option to treat various diseases, but there are some drawbacks also like some immunogenic issues, safety, stability problem of protein, degradation of protein in various conditions.
Cite this article:
Arindam Chakraborty, Dipak Kumar Singha, Manas Chakraborty, Payel Mukherjee. Protein Therapeutics: An Updated Review. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(3):253-7. doi: 10.52711/2231-5659.2021.00040
Arindam Chakraborty, Dipak Kumar Singha, Manas Chakraborty, Payel Mukherjee. Protein Therapeutics: An Updated Review. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(3):253-7. doi: 10.52711/2231-5659.2021.00040 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2021-11-3-12
1. Amaburton AF, Drew CR. Protein therapy; the clinical use of a new protein preparation. J Natl Med Assoc. 1949; 41(2): 74-77.
2. Chakraborty A., Mukherjee P., Chakraborty M. Peptide Therapy: A Promising Approach in Cancer Treatment. Int. J. Pharm. Technol. Biotechnol. 2020; 7(3): 74-81.
3. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des. 2013; 81: 136–147.
4. Leader B, Baca QJ, Golan DE. Protein therapeutics: a Summary and pharmacological classification. Nat Rev Drug Discov. 2008; 7: 21–39.
5. Tang L, Persky AM, Hochhaus G, Meibohm B. Pharmacokinetic aspects of biotechnology products. J Pharm Sci. 2004; 93: 2184–2204.
6. Akash MSH, Rehman K, Chen S. Role of inflammatory Mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem, 2013a; 114: 525–531.
7. Akash MSH, Rehman K, Sun H, Chen S. Interleukin-1 receptor antagonist improves normoglycemia and insulin sensitivity in diabetic Goto-Kakizaki-rats. Eur J Pharmacol. 2013b; 701: 87–95.
8. Karacali S, İzzetoğlu S, Deveci R. Glycosylation changes leading to the increase in size on the common core of N-glycans, required enzymes, and related cancer-associated Proteins. Turk J Biol. 2014; 38: 754–771.
9. Ibrahim M, Farooq T, Hussain N, Hussain A, Gulzar T, Hussain I, Akash MSH, Rehmani FS. Acetyl and butyryl cholinesterase inhibitor sesquiterpene lactones from Amberboa ramosa. Chem Cent J. 2013; 7: 116.
10. Caravella J, Lugovskoy A. Design of next-generation protein therapeutics. Current Opinion in Chemical Biology.2010; 14:520–528.
11. Atkinson AJ. Introduction to clinical pharmacology. In: Atkinson, AJ, Daniels, CE, Dedrick, RL, Grudzinskas, CV, Markey, SP eds. Principles of Clinical Pharmacology. 2001.
12. Sutradhar, K. B., Khatun, S., Al Mamun, A., and Begum, M. Distribution and elimination of protein therapeutics: A review. Stamford Journal of Pharmaceutical Sciences, 2011; 4 (2), 1-12
13. Mrsny RJ. Strategies for targeting protein therapeutics to selected tissues and cells. Expert Opin Biol Ther, 2004; 4: 65–73.
14. Jayapal KP, Wlaschin KF, Hu W, Yap MG. Recombinant protein therapeutics from CHO cells-20 years and counting. Chem Eng Prog, 2007; 103: 40.
15. Kelley BD. Biochemical engineering: bioprocessing of therapeutic proteins. Curr Opin Biotechnol, 2001; 12: 173–174.
16. Kamionka M. Engineering of therapeutic proteins production inEscherichia coli. Curr Pharm Biotechnol, 2011; 12: 268–274.
17. Wang H, Chen X, Huang Z, Zhou B, Jia G, Liu G, Zhao H. Expression and purification of porcine PID1 gene in Escherichia coli. Turk J Biol, 2014; 38: 523–527.
18. Ahmad I, Rubbab T, Deeba F, Naqvi SMS. Optimization of E. Coli culture conditions for efficient DNA uptake by Electroporation. Turk J Biol, 2014; 38: 568–573.
19. Martemyanov KA, Shirokov VA, Kurnasov OV, Gudkov AT, Spirin AS. Cell-free production of biologically active Polypeptides: application to the synthesis of antibacterial peptide cecropin. Protein Expr Purif, 2001; 21: 456–461.
20. Janne J, Hyttinen JM, Peura T, Tolvanen M, Alhonen L, Halmekyto M. Transgenic animals as bioproducers of therapeutic proteins. Ann Med, 1992; 24: 273–280.
21. Tariq, Muhammad and Akash, Muhammad Sajid Hamid and Rehman, Kanwal and shuqing, chen. Development of therapeutic proteins: Advances and challenges. Turkish Journal of Biology.2015; 39. 10.3906/biy-1411-8.
22. Nayak AK. Advances in therapeutic protein production and delivery. Int J Pharm Pharm Sci. 2010; 2: 1–5.
23. Mahmood I, Green MD. Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins. Clin Pharmacokinet.2005; 44 (4): 331-347.
24. Braeckman R. Pharmacokinetics and pharmacodynamics of protein therapeutics. In Reid ER, editor. Peptides and Protein Drug Analysis. New York, NY, USA: Marcel Dekker Inc, 2000; 633–669.
25. Zhao L, Ji P, Li Z, Roy P, Sahajwalla CG. The antibody drug absorption following subcutaneous or intramuscular Administration and its mathematical description by coupling physiologically based absorption process with the conventional Compartment pharmacokinetic model. J Clin Pharmacol. 2013; 53: 314–325.
26. Mannaerts BM, Geurts TB, Odink J. A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration. Hum Reprod. 1998; 13: 1461–1464.
27. Montagna M, Montillo M, Avanzini MA, Tinelli C, Tedeschi A, Visai L, Ricci F, Vismara E, Morra E, Regazzi M. Relationship Between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia. Haematologica. 2011; 96: 932–936.
28. Lin JH. Pharmacokinetics of biotech drugs: peptides, proteins, and monoclonal antibodies. Curr Drug Metab. 2009; 10: 661–691.
29. Porter CJ, Edwards GA, Charman SA. Lymphatic transport of proteins after s.c. injection: implications of animal model Selection. Adv Drug Deliv Rev. 2005; 50: 157–171.
30. Chien JY, Ho RJ. Drug delivery trends in clinical trials and translational medicine. J Pharm Sci. 2008; 97: 2543–2547.
31. Maher S, Brayden DJ. Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. Drug Discov Today Technol. 2012; 9: e113–e119.
32. Hamman JH, Steenekamp JH. Oral peptide drug delivery: strategies to overcome challenges. Hoboken, NJ, USA: Wiley-VCH.2011; 71–90.
33. Orive G, Gascon AR, Hernandez RM, Dominguez-Gil A, Pedraz JL. Techniques: new approaches to the delivery of biopharmaceuticals. Trends Pharmacol Sci. 2004; 25: 382–387.
34. Mohler MA, Cook JE, Baumann G. Binding proteins of protein therapeutics. In erraiolo BL, Mohler MA, Gloff CA, editors. Protein Pharmacokinetics and Metabolism. New York, NY, USA: Springer, 1192; 35–71.
35. Lin JH. Pharmacokinetics of biotech drugs: peptides, proteins, and monoclonal antibodies. Curr Drug Metab. 2009; 10: 661–691.
36. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev.2008; 60: 1421–1434.
37. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009; 8: 2861–2871.
38. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res.1990; 2: 167-9.
39. Maack T. Renal handling of low molecular proteins. Am J Med.1975; 58(1): 57-64.
40. Tang L, Meibohm B. Pharmacokinetics of peptides and proteins. In Meibohm B, editors. Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development. Weinheim, Germany: Wiley-VCH.2006; 17–44.
41. Louse PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, Hamilton A, Dowlati A, Mani S, Rudek MA et al. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res.2012; 18: 2954–2963.
42. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult Human hepatocytes in primary culture. Mol Pharmacol.1993; 44: 707–715.
43. Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts andlessons for drug development. BioDrugs.2010; 24: 23–39.
44. Meibohm B, Zhou H. Characterizing the impact of renal Impairment on the clinical pharmacology of biologics. J Clin Pharmacol. 2012; 52: 54S–62S.
45. Kompella A, Lee VHL. Pharmacokinetics of peptide and protein drugs. In: Lee VHL, editor. Peptide and protein drug delivery. New York: Marcel Dekker Inc. 1991; 391-484.
46. Mahmood, I. Pharmacokinetics and pharmacodynamic considerations in the development of therapeutic proteins. In: Mahmood I. Eds. Clinical Pharmacology of Therapeutic Proteins. Pine House Publishers, 2006; 123–174.
47. Mahmood I. Methods to determine Pharmacokinetic profiles of therapeutic proteins. Drug Discovery Today: Technologies.2008; 5(2–3): e65-e69.
48. Preusch PC. Equilibrative and concentrative drug transport mechanisms. In: Atkinson AJ, Daniels CE, Dedrick RL, et al., eds. Principles of clinical pharmacology. San Diego (CA): Academic Press.2001; 201-22.
49. Qarawi, and Farah, Farah and Elhaj, B.M. A review on therapeutic proteins: stability aspects and clinical implications.2019; 10. 1-7.
50. Shih HH. Discovery process for antibody-based therapeutics. Editor. Development of antibody-based therapeutics. New York, NY, USA: Springer, 2012; 9–32.
51. Strohl WR, Knight DM. Discovery and development of biopharmaceuticals: current issues. Curr Opin Biotechnol. 2009; 20: 668–672.
52. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol.2006; 6: 343–357.
53. Stebbings R, Poole S, Thorpe R. Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol.2009; 20: 673–677.
54. Jiskoot W, Randolph TW, Volkin DB, Middaugh CR, Schoneich C, Winter G, Friess W, Crommelin DJ, Carpenter JF. Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci.2012; 101: 946–954.
55. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci USA.2009; 106: 11937–11942.
56. Akash MSH, Rehman K, Chen S. Natural and synthetic polymers as drug carriers for delivery of therapeutic proteins Polym Rev: 2015a.